🔗 Share this article

Given that the US undertakes unprecedented changes to its vaccine schedules, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and epidemiologist who first made her name by casting doubt on coronavirus shots during the global health crisis and has concentrated on potential deaths after Covid immunization in her brief time at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Schedule

Health officials had intended to announce major changes to the pediatric immunization program in December, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would put the US at odds with many the world with no evidence for benefit. The announcement has been delayed until the new year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A Shift at the Regulatory Body

Høeg's temporary position might represent a closer partnership between the drug and biologics divisions as Høeg and Dr. Prasad strengthen their influence at the FDA – and it suggests a greater focus upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has often pushed for halting specific pediatric immunization guidelines in the US so as to align more in line with Denmark, a society with universal health coverage and a number of inhabitants about the population of Wisconsin’s.

To date public appearances, she has kept her attention on immunizations – typically the domain of Prasad, director of the FDA’s vaccine center – instead of drug regulation.

Questions Over Qualifications

Høeg has little discernible background in drug development, oversight or administrative roles, which has been customary for previous directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the agency head and CBER since spring.

“It seems she lacks to have the necessary background” for leading the CDER, said Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She has no expertise in running a major agency. She is not an expert in industry regulation.”

Former heads of the center would “grasp laws and regulations and the underlying principles of medication creation”, said a former acting FDA commissioner. “Frankly, she has not acquired the kind of background that prior appointees who led the center have had.”

The drug center has an vast portfolio at the FDA, she pointed out.

“The public just focuses on the new drug program, but the off-patent medication office approves thousands of off-brand pharmaceuticals. There is also a biosimilars division, OTC medication office and more, and all of those have to be managed,” Dr. Woodcock noted. “The area you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a substantial administrative component to the position, which oversees in excess of 5,000 employees. “It’s a huge management job, if you do it right,” Woodcock said.

Official Statement and Contentious Programs

Regarding questions about Høeg’s qualifications and whether this selection indicates greater collaboration among FDA leaders on vaccines, a spokesperson responded that the “concerns stem from flawed premises”.

“Her resume aligns with the duties of her position,” the spokesperson said, citing the period Høeg spent guiding the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the commissioner’s recently launched expedited review system, a disputed expedited drug-approval program that allegedly troubled her preceding directors. “By what process are these medications being picked for this fast-track system? Who takes the decisions?” Howard said. “There is a lot of lack of transparency going on at the regulatory body right now.”

Overall, he said, “the agency looks to be trending towards less stringent rules of all drugs, aside from shots.”

Documented Past Work on Vaccines

With vaccines, Høeg has a more established, if concerning, history, critics have noted. She authored a research paper using unconfirmed volunteer-provided data to assess the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to indicate Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the incoming federal leadership featured revising guidelines for recently developed shots and ending “optional” vaccines, she said after the election on a online show. At the agency, Høeg has reportedly suggested preventing young men from obtaining Covid vaccinations.

“She is an complete dogmatist who starts off with her preconceived notions and reverse-engineers to fit the science in a extremely misleading, dishonest way,” Dr. Howard argued.

Taking Control and a “Push for Payback”

Dr. Høeg became part of other contrarians, {like|